- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06192004
Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD (LOOP)
An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD
This is an observational, prospective, multicenter study conducted in the US to gather evidence in the context of lung cancer to complement the development of a digital solution.
Patients initiating treatment for non-small cell lung cancer (NSCLC) will be prospectively followed to characterize risk factors, signs, and symptoms leading to onset, diagnosis, and treatment of pneumonitis/ILD should it occur.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an observational, prospective, multicenter study conducted in the US to gather evidence in the context of lung cancer to complement the development of a digital solution.
Data will be collected prospectively from study sites using eCRFs and remotely from patients using a digital health tool.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- Recruiting
- Research Site
-
-
Illinois
-
Skokie, Illinois, United States, 60076
- Recruiting
- Research Site
-
-
Michigan
-
Troy, Michigan, United States, 48098
- Recruiting
- Research Site
-
-
New Jersey
-
Mickleton, New Jersey, United States, 08056
- Recruiting
- Research Site
-
-
Ohio
-
Massillon, Ohio, United States, 44646
- Recruiting
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient must be 18 years of age or older, at the time of signing the ICF (Informed consent).
- Have histologically or cytologically documented unresectable Stage III or Stage IV NSCLC.
- Are initiating treatment with an FDA (Food and Drug Administration)-approved immune checkpoint inhibitor (alone or in combination with other agents), antibody drug conjugate, or small molecule EGFR inhibitor.
- Minimum life expectancy of 12 weeks at the time of signing the ICF.
- Able and willing to provide written signed informed consent.
- Able and willing to use the digital health tool throughout the duration of the study.
Exclusion Criteria:
- Concurrent participation in a research study or a clinical trial.
- Unable to receive SoC for the treatment and management of NSCLC including clinical or imaging assessments for up to 6 months.
- Judgment by the Investigator that the patient is unsuitable to participate in the study and/or the patient is unlikely to comply with study procedures and requirements.
- Confirmed or suspected diagnosis of pneumonitis/ILD at the time of signing ICF. This does not apply to historical pneumonitis/ILD events that have resolved prior to signing ICF.
- More than 2 weeks have passed from the administration of the first dose of qualifying FDA-approved treatment.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Prospective Cohort
NSCLC patients initiating an approved treatment with risk of pneumonitis/ILD.
|
Not applicable since Observational Study
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity, Specificity, positive predictive value (PPV), negative predictive value (NPV) and odds ratio (OR) of the algorithm
Time Frame: Approximately 6 months
|
To complement the development of the algorithm to identify a patient at risk of pneumonitis/ILD.
|
Approximately 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of pneumonitis/ILD per grade
Time Frame: Approximately 6 months
|
To characterize the onset and evolution over time of pneumonitis/ILD in patient receiving SoC for NSCLC.
|
Approximately 6 months
|
Time from anti-tumor treatment initiation to suspicion of pneumonitis/ILD
Time Frame: Approximately 6 months
|
To characterize the onset and evolution over time of pneumonitis/ILD in patient receiving SoC for NSCLC.
|
Approximately 6 months
|
Time from anti-tumor treatment initiation to pneumonitis-related anti-tumor treatment dose delay, dose reduction, and/or discontinuation
Time Frame: Approximately 6 months
|
To characterize the onset and evolution over time of pneumonitis/ILD in patient receiving SoC for NSCLC.
|
Approximately 6 months
|
Time from pneumonitis-related treatment or diagnosis to anti-tumor treatment dose delay, dose reduction, and/or discontinuation
Time Frame: Approximately 6 months
|
To characterize the onset and evolution over time of pneumonitis/ILD in patient receiving SoC for NSCLC.
|
Approximately 6 months
|
Time from pneumonitis-related anti-tumor treatment discontinuation to rechallenge
Time Frame: Approximately 6 months
|
To characterize the onset and evolution over time of pneumonitis/ILD in patient receiving SoC for NSCLC.
|
Approximately 6 months
|
Resources used for the monitoring, diagnosis, or management of pneumonitis/ILD
Time Frame: Approximately 6 months
|
The use of corticosteroids, test(s) requirements for diagnosis, hospitalization will be evaluated to characterize the onset and evolution over time of pneumonitis/ILD in patient.
|
Approximately 6 months
|
Change from baseline in St George's Respiratory Questionnaire (SGRQ-I) health status score
Time Frame: Approximately 6 months
|
St George's Respiratory Questionnaire for Idiopathic Pulmonary Fibrosis
|
Approximately 6 months
|
Change from baseline in 5 Level EuroQoL 5 Dimension Questionnaire (EQ-5D-5L) health status score
Time Frame: Approximately 6 months
|
5 Level EuroQoL 5 Dimension Questionnaire
|
Approximately 6 months
|
Change from baseline in symptom severity score
Time Frame: Approximately 6 months
|
Daily symptom severity rating
|
Approximately 6 months
|
Compliance rate of patient-reported symptoms
Time Frame: Approximately 6 months
|
Daily symptom severity rating
|
Approximately 6 months
|
Compliance rate of patient collected pulse oximetry assessment
Time Frame: Approximately 6 months
|
Daily pulse oximetry reading
|
Approximately 6 months
|
Sensitivity, specificity, PPV, NPV and OR of the algorithm
Time Frame: Approximately 6 months
|
To assess algorithm performance in identifying Pneumonitis/ILD and other lung/respiratory/thoracic-related events including but not limited to: tumor progression, pneumonia, COVID-19.
|
Approximately 6 months
|
Incidence of pneumonitis/ILD and other lung/respiratory/thoracic-related events
Time Frame: Approximately 6 months
|
The incidence of pneumonitis/ILD and other lung/respiratory/thoracic-related events including but not limited to tumor progression, pneumonia, COVID-19, and associations and correlations with patient-generated data on eCOA will be assessed.
|
Approximately 6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D7680C00001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
Clinical Trials on None (Observational Study)
-
Taysha Gene Therapies, Inc.Withdrawn
-
University of Castilla-La ManchaRecruitingKnee OsteoarthritisSpain
-
AstraZenecaRecruiting
-
University of ExeterRecruiting
-
Vanderbilt University Medical CenterUniversity of California, Los AngelesRecruitingTourette SyndromeUnited States
-
Major Extremity Trauma Research ConsortiumRecruiting
-
Medialis Ltd.Metabolic Support UKCompletedX-linked Hypophosphatemia (XLH)United Kingdom
-
PfizerCompletedTransthyretin Amyloidosis | Transthyretin Gene MutationsUnited States, France, Spain, Taiwan, Israel, Korea, Republic of, Denmark, Canada, Netherlands, Japan, Sweden, Brazil, Mexico, Argentina, Portugal, Belgium, Bulgaria, Cyprus, Germany, Italy, Malaysia, Romania, Saudi Arabia, Turkey, United...
-
German Cancer Research CenterActive, not recruitingCancer-related FatigueGermany
-
UNC Lineberger Comprehensive Cancer CenterAmerican Cancer Society, Inc.Completed